TNF and psoriasis vulgaris: Among these, tumor necrosis factor alpha (TNF-α) inhibitors (adalimumab, etanercept, infliximab) and newer agents targeting interleukin (IL) (IL-12/23) (ustekinumab), IL-17 (secukinumab, ixekizumab), and IL-23 (guselkumab, risankizumab) have demonstrated remarkable clinical efficacy and safety in moderate-to-severe plaque psoriasis [8].